tPA level

Higher baseline tPA was associated with increased incident diabetes risk in the placebo group, independent of traditional diabetes risk factors and their 1-year changes, and independent of all other b

Effect: decline; HR 1.13; CI: 95% CI 1.03, 1.24

Higher baseline tPA was associated with increased incident diabetes risk in the placebo group, independent of traditional diabetes risk factors and their 1-year changes, and independent of all other b

Effect: decline; HR 1.13; CI: 95% CI 1.03, 1.24

Higher baseline tPA was associated with increased incident diabetes risk in the placebo group, independent of traditional diabetes risk factors and their 1-year changes, and independent of all other b

Effect: decline; HR 1.13; CI: 95% CI 1.03, 1.24

Higher baseline tPA was associated with increased incident diabetes risk in the placebo group, independent of traditional diabetes risk factors and their 1-year changes, and independent of all other b

Effect: decline; HR 1.13; CI: 95% CI 1.03, 1.24

Higher baseline tPA was associated with increased incident diabetes risk in the placebo group, independent of traditional diabetes risk factors and their 1-year changes, and independent of all other b

Effect: decline; HR 1.13; CI: 95% CI 1.03, 1.24

Higher baseline tPA was associated with increased incident diabetes risk in the placebo group, independent of traditional diabetes risk factors and their 1-year changes, and independent of all other b

Effect: decline; HR 1.13; CI: 95% CI 1.03, 1.24

Higher baseline tPA was associated with increased incident diabetes risk in the placebo group, independent of traditional diabetes risk factors and their 1-year changes, and independent of all other b

Effect: decline; HR 1.13; CI: 95% CI 1.03, 1.24

Higher baseline tPA was associated with increased incident diabetes risk in the placebo group, independent of traditional diabetes risk factors and their 1-year changes, and independent of all other b

Effect: decline; HR 1.13; CI: 95% CI 1.03, 1.24

Higher baseline tPA was associated with increased incident diabetes risk in the placebo group, independent of traditional diabetes risk factors and their 1-year changes, and independent of all other b

Effect: decline; HR 1.13; CI: 95% CI 1.03, 1.24

Higher baseline tPA was associated with increased incident diabetes risk in the placebo group, independent of traditional diabetes risk factors and their 1-year changes, and independent of all other b

Effect: decline; HR 1.13; CI: 95% CI 1.03, 1.24

Higher baseline tPA was associated with increased incident diabetes risk in the placebo group, independent of traditional diabetes risk factors and their 1-year changes, and independent of all other b

Effect: decline; HR 1.13; CI: 95% CI 1.03, 1.24

Higher baseline tPA was associated with increased incident diabetes risk in the placebo group, independent of traditional diabetes risk factors and their 1-year changes, and independent of all other b

Effect: decline; HR 1.13; CI: 95% CI 1.03, 1.24

Higher baseline tPA was associated with increased incident diabetes risk in the placebo group, independent of traditional diabetes risk factors and their 1-year changes, and independent of all other b

Effect: decline; HR 1.13; CI: 95% CI 1.03, 1.24

Higher baseline tPA was associated with increased incident diabetes risk in the placebo group, independent of traditional diabetes risk factors and their 1-year changes, and independent of all other b

Effect: decline; HR 1.13; CI: 95% CI 1.03, 1.24

Higher baseline tPA was associated with increased incident diabetes risk in the placebo group, independent of traditional diabetes risk factors and their 1-year changes, and independent of all other b

Effect: decline; HR 1.13; CI: 95% CI 1.03, 1.24

Higher baseline tPA was associated with increased incident diabetes risk in the placebo group, independent of traditional diabetes risk factors and their 1-year changes, and independent of all other b

Effect: decline; HR 1.13; CI: 95% CI 1.03, 1.24

Higher baseline tPA was associated with increased incident diabetes risk in the placebo group, independent of traditional diabetes risk factors and their 1-year changes, and independent of all other b

Effect: decline; HR 1.13; CI: 95% CI 1.03, 1.24

Higher baseline tPA was associated with increased incident diabetes risk in the placebo group, independent of traditional diabetes risk factors and their 1-year changes, and independent of all other b

Effect: decline; HR 1.13; CI: 95% CI 1.03, 1.24

Higher baseline tPA was associated with increased incident diabetes risk in the placebo group, independent of traditional diabetes risk factors and their 1-year changes, and independent of all other b

Effect: decline; HR 1.13; CI: 95% CI 1.03, 1.24

Higher baseline tPA was associated with increased incident diabetes risk in the placebo group, independent of traditional diabetes risk factors and their 1-year changes, and independent of all other b

Effect: decline; HR 1.13; CI: 95% CI 1.03, 1.24

Higher baseline tPA was associated with increased incident diabetes risk in the placebo group, independent of traditional diabetes risk factors and their 1-year changes, and independent of all other b

Effect: decline; HR 1.13; CI: 95% CI 1.03, 1.24

Higher baseline tPA was associated with increased incident diabetes risk in the placebo group, independent of traditional diabetes risk factors and their 1-year changes, and independent of all other b

Effect: decline; HR 1.13; CI: 95% CI 1.03, 1.24

Higher baseline tPA was associated with increased incident diabetes risk in the placebo group, independent of traditional diabetes risk factors and their 1-year changes, and independent of all other b

Effect: decline; HR 1.13; CI: 95% CI 1.03, 1.24

Higher baseline tPA was associated with increased incident diabetes risk in the placebo group, independent of traditional diabetes risk factors and their 1-year changes, and independent of all other b

Effect: decline; HR 1.13; CI: 95% CI 1.03, 1.24

Higher baseline tPA was associated with increased incident diabetes risk in the placebo group, independent of traditional diabetes risk factors and their 1-year changes, and independent of all other b

Effect: decline; HR 1.13; CI: 95% CI 1.03, 1.24

Higher baseline tPA was associated with increased incident diabetes risk in the placebo group, independent of traditional diabetes risk factors and their 1-year changes, and independent of all other b

Effect: decline; HR 1.13; CI: 95% CI 1.03, 1.24

Higher baseline tPA was associated with increased incident diabetes risk in the placebo group, independent of traditional diabetes risk factors and their 1-year changes, and independent of all other b

Effect: decline; HR 1.13; CI: 95% CI 1.03, 1.24